- Home
- Reducing Cardiovascular Risk With Effective Management Of LDL Cholesterol - A Roundtable Discussion
Reducing Cardiovascular Risk With Effective Management Of LDL Cholesterol - A Roundtable Discussion
Topic:
- Prevention
Available Credit:
- Not accredited
Course Published On:
Course Expiry Date:
Overview
This roundtable is designed to provide clinicians with a better understanding of the long-term CV risks of LDL-C exposure. In addition to reviewing the pathogenesis of atherosclerosis and assessing the long-term implications of elevated LDL-C, this meeting will consider current guidance around controlling LDL-C, the challenges in achieving LDL-C targets, and evaluating how emerging strategies are contributing to LDL-C management.
Each chapter will comprise of a short presentation by the named medical expert followed by a panel discussion amongst all faculty.
Target Audience
- Healthcare Professionals
- General Cardiologists
Learning Objectives
Upon completion of this activity, participants will be able to:
- Outline the pathogenic nature and clinical risk of extended exposure to elevated LDL-C
- Describe the clinical challenges in achieving guidance-based LDL-C goals
- Compare and contrast LDL-C lowering therapies
This course is not accredited
Related Courses
Elevating Understanding and Management of Hypertriglyceridemia
- 1.25
Published:
Learning objectives
- Understand HTG as a risk factor for acute and chronic illness
- Describe current guideline directed management of HTG
- Recognise the gaps and challenges present in current guideline directed management of HTG
- Recall emerging trial data for novel pharmacological targets
- Use guidelines, trial data & expert opinion to develop individualised treatment strategies for high-risk patients
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
Examining a Complex Heart Failure Case
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use
- 2.00
Published:
Learning objectives
- Describe the burden of ASCVD in type 2 diabetes
- Assign risk of future CV events to individuals with type 2 diabetes
- Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
- Recall trial data of anti-diabetes medications that reduce ASCVD risk
- Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
- Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
- Adopt anti-diabetic therapies with proven ASCVD benefit
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity